CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease

Y. Courtney; M. Pandit; L. S. van Dam; S. Younis; S. Rasouli; M. Zhang; Y. Chaichian; S. Parsafar; T. V. Lanz; E. Arends; C. van Kooten; Y. K. O. Teng; M. Hagen; A. Wirsching; F. Muller; A. Mackensen; A. Bozec; R. Grieshaber-Bouyer; G. Schett; W. H. Robinson

doi:10.64898/2026.10.24.761515

AI summary · DOI: 10.64898/2026.10.24.761515 · bioRxiv: Immunology

CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease

Y. Courtney, M. Pandit, L. S. van Dam, S. Younis, S. Rasouli, M. Zhang, Y. Chaichian, S. Parsafar,

and 12 more authors

T. V. Lanz, E. Arends, C. van Kooten, Y. K. O. Teng, M. Hagen, A. Wirsching, F. Muller, A. Mackensen, A. Bozec, R. Grieshaber-Bouyer, G. Schett, W. H. Robinson

Original paper Published on 02 Nov. 2026 bioRxiv preprint License: CC BY 4.0 Also in: fr

How to read this summary? Illustrated guide

The essentials

CD19-CAR T-cell therapy depleted EBV-positive autoreactive B cells and reset the reconstituted repertoire, an effect associated with sustained drug-free remission.

Based on the abstract only: check the details in the original paper.

Question

The study asks whether eliminating EBV-positive autoreactive B cells contributes to durable remission after CD19-CAR T-cell therapy in autoimmune disease. It compares these cells and clinical outcomes with rituximab treatment.

Method

The authors used EBV-seq to profile EBV-positive B cells from patients treated with CAR T cells (6 with systemic lupus erythematosus, 3 with inflammatory myopathy, and 3 with systemic sclerosis) or rituximab (15 patients), and recombinantly expressed antibodies to test antigen specificity. They also compared treatment effects on EBV-positive cells in vitro.

Findings

Result At baseline, patients had enriched EBV-positive B cells with class-switched, hypermutated antibodies and an activated antigen-presenting phenotype.
See the passage in the paper
At baseline, EBV+ B cells were enriched relative to healthy donors, class-switched and hypermutated, expressed the latency III program with heightened antigen-presentation signatures, and encoded autoantibodies.
Result CAR T-cell therapy depleted EBV-positive B cells and was followed by a repertoire shift toward minimally mutated IgM-positive cells that were largely non-autoreactive.
See the passage in the paper
CAR T cells, but not rituximab, depleted EBV+ B cells and shifted the reconstituted repertoire towards IgM+, minimally mutated, largely non-autoreactive cells, consistent with infection of newly generated B cells.
Result Following rituximab, EBV-positive B cells retained an activated, class-switched, hypermutated, autoreactive profile.
See the passage in the paper
After rituximab, EBV+ B cells retained a class-switched, hypermutated and autoreactive with an activated antigen-presenting phenotype.
Result Sustained drug-free remission was observed in 8 of 12 CAR T-cell-treated patients and none of the 15 rituximab-treated patients.
See the passage in the paper
Sustained drug-free remission occurred in 8/12 CAR T-cell-treated versus 0/15 rituximab-treated patients.
Result In vitro, EBV-positive B cells resisted anti-CD20 and anti-CD19 antibodies but were killed by CAR T cells and a CD19 T-cell engager.
See the passage in the paper
In vitro, EBV+ B cells resisted anti-CD20 and anti-CD19 antibodies but were killed by CAR T cells and a CD19 T-cell engager.

Limitations

The study reports a small CAR T-cell-treated patient group, with 12 patients across three autoimmune diseases.
The findings show an association between repertoire resetting and remission, but do not establish that repertoire resetting causes sustained remission.

Why it matters

The authors argue that CD19-CAR T-cell therapy may achieve sustained drug-free remission in part by resetting the EBV-positive autoreactive B-cell repertoire, unlike rituximab. Their results also point to EBV-positive B cells as targets that can resist antibody-based depletion but remain susceptible to cellular approaches.

Written by AI from the paper. Passages are checked word for word against the text we analysed; the rest may contain errors.

AI-generated keywords: Epstein–Barr virus; CD19-CAR T-cell therapy; autoreactive B cells; autoimmune disease; drug-free remission

Read further

Comprehensive Summary
Layman's Summary
Blog article
Original abstract

The study examines whether eliminating Epstein–Barr virus–positive (EBV+) B cells helps explain durable remission after CD19 chimeric antigen receptor (CAR) T-cell therapy for autoimmune disease. EBV can reprogram autoreactive B cells into activated antigen-presenting cells, potentially sustaining harmful immune responses. The authors compared EBV+ B cells from people treated with CD19-CAR T cells or rituximab, an anti-CD20 antibody, and investigated whether these cells produced antibodies that recognized self-antigens. They used EBV B-cell sequencing (EBV-seq) to profile cells from 12 CAR T-cell-treated patients: six with systemic lupus erythematosus, three with inflammatory myopathy, and three with systemic sclerosis. They also studied 15 rituximab-treated patients and compared baseline findings with those from healthy donors. To determine antibody specificity, the researchers recombinantly expressed antibodies encoded by the EBV+ B cells. In laboratory experiments, they tested the cells’ responses to anti-CD20 and anti-CD19 antibodies, CAR T cells, and a CD19 T-cell engager. At baseline, patients had a higher proportion of EBV+ B cells than healthy donors. These cells tended to be class-switched and highly mutated, features consistent with prior immune activation and maturation. They also showed a latency III EBV program and increased antigen-presentation signatures. The antibodies they encoded included autoantibodies, suggesting that EBV-infected B cells may participate in autoreactive immune responses. After CD19-CAR T-cell therapy, EBV+ B cells were depleted, and the reappearing B-cell repertoire shifted toward IgM-positive, minimally mutated cells. Most of these cells were not autoreactive. The authors interpret this pattern as consistent with newly generated B cells becoming infected, rather than the earlier mature, autoreactive EBV+ population simply returning. By contrast, after rituximab treatment, EBV+ B cells persisted with a class-switched, highly mutated, autoreactive, and activated antigen-presenting profile. Sustained drug-free remission was reported in 8 of 12 CAR T-cell-treated patients and none of the 15 rituximab-treated patients. In vitro, EBV+ B cells resisted anti-CD20 and anti-CD19 antibodies but were killed by CAR T cells and a CD19 T-cell engager. The findings suggest that deeper elimination of EBV+ autoreactive B cells, followed by reconstitution with a less mature and largely non-autoreactive repertoire, may contribute to sustained remission after CD19-CAR T-cell therapy. The persistence of activated, autoreactive EBV+ cells after rituximab may help explain why B-cell depletion with that treatment did not produce drug-free remission in this cohort. These results support further investigation of EBV+ B cells as a therapeutic target, but they do not establish that their removal causes remission. The study has important limitations. It describes a relatively small, non-randomized comparison involving 12 CAR T-cell recipients and 15 rituximab recipients across several autoimmune diseases. Because the supplied report is an abstract rather than the full paper, details needed to assess patient selection, treatment differences, follow-up, statistical analyses, and assay validation are unavailable. The remission comparison therefore does not prove that one treatment is superior or establish a causal mechanism. The findings are from a preprint and require confirmation in larger, carefully controlled studies.

Could Removing EBV-Infected B Cells Help Explain Lasting Remission?

For some people with autoimmune disease, CD19 CAR T-cell therapy has been followed by sustained remission without ongoing medication. Why the effects might last is still an open question. The preprint “CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease,” by Y. Courtney, M. Pandit, L. S. van Dam, S. Younis, S. Rasouli, M. Zhang et al., explores one possible clue: the treatment’s effect on B cells infected with Epstein–Barr virus (EBV).

EBV is a common virus, but infected B cells may do more than carry it. The virus can alter B-cell behavior, encouraging cells to become activated and better at presenting antigens to other immune cells. If some of these B cells also react to the body’s own tissues, they could help maintain damaging immune responses. The researchers asked whether removing these cells might be connected to durable remission after CD19 CAR T-cell therapy.

What the Researchers Examined

The team used a method called EBV B-cell sequencing, or EBV-seq, to study EBV-positive (EBV+) B cells from 12 people treated with CD19 CAR T cells: six with systemic lupus erythematosus, three with inflammatory myopathy, and three with systemic sclerosis. They also examined samples from 15 people treated with rituximab, an antibody that targets CD20, and compared baseline findings with those from healthy donors.

To find out whether the EBV+ cells made antibodies against the body’s own targets, the researchers recreated antibodies encoded by the cells and tested what those antibodies recognized. They also tested how EBV+ B cells responded in laboratory experiments to anti-CD20 and anti-CD19 antibodies, CAR T cells, and a CD19 T-cell engager.

A More Activated B-Cell Profile in Autoimmune Disease

At baseline, people with autoimmune disease had a higher proportion of EBV+ B cells than healthy donors. Many of these cells had switched antibody class and accumulated substantial mutations. These features generally reflect a history of immune activation and maturation. The cells also showed a latency III EBV program and increased signatures linked to antigen presentation.

Some of the antibodies produced from these cells recognized self-antigens. This result suggests that EBV-infected B cells may take part in autoreactive immune responses, although it does not by itself show that they cause autoimmune disease or keep it active.

Different Patterns After CAR T-Cell Therapy and Rituximab

After CD19 CAR T-cell therapy, the researchers observed depletion of EBV+ B cells. As the B-cell population returned, it was enriched for IgM-positive cells with relatively few mutations. Most of the returning cells tested were not autoreactive. The authors interpret this pattern as consistent with newly generated B cells becoming infected, rather than the original mature, autoreactive EBV+ population simply reappearing.

The pattern after rituximab was different. EBV+ B cells persisted with features of a more mature and activated population: class switching, many mutations, autoreactivity, and increased antigen-presentation signatures. In laboratory experiments, these cells resisted anti-CD20 and anti-CD19 antibodies, but were killed by CAR T cells and by a CD19 T-cell engager. This offers a possible explanation for why some EBV+ cells might escape antibody-based treatment while remaining vulnerable to approaches that directly engage T cells.

What the Remission Results May Mean

Sustained drug-free remission was reported in 8 of the 12 CAR T-cell-treated patients and in none of the 15 rituximab-treated patients. The authors suggest that deeper removal of EBV+ autoreactive B cells, followed by a less mature and largely non-autoreactive B-cell repertoire, may contribute to lasting remission after CAR T-cell therapy. Conversely, persistent activated EBV+ cells after rituximab could be one factor associated with the lack of drug-free remission in this group.

These findings make EBV+ B cells an intriguing subject for further research. They do not establish that eliminating these cells causes remission. CAR T-cell therapy and rituximab differ in how they work, and the study cannot show that the observed B-cell changes alone explain the different outcomes.

Important Caveats

The comparison was small: it included 12 CAR T-cell recipients and 15 rituximab-treated patients.
It was non-randomized and included several different autoimmune diseases, so the groups may not be directly comparable.
The available report is an abstract, leaving important details about patient selection, treatment differences, follow-up, statistical analyses, and assay validation unavailable.
The remission figures do not prove that one treatment is superior or establish a causal mechanism.
The findings are from a preprint and need confirmation in larger, carefully controlled studies.

The Takeaway

The study presents a plausible link between CD19 CAR T-cell therapy, changes in the EBV+ B-cell population, and durable drug-free remission. It suggests that removing mature, autoreactive EBV+ cells may help reset the B-cell repertoire. For now, that remains a hypothesis rather than a demonstrated explanation. Further research will need to determine whether these cells are a useful therapeutic target and whether their removal meaningfully contributes to remission.

Created on 09 Nov. 2026

Was this synthesis useful?

Score: 0

Ask questions about this paper to our AI assistant

How to chat with this paper? Illustrated guide

You can also chat with multiple papers at once here.

AI assistant instructions?

Tools for this paper

Explain it differently 1 free rewrite left today

Save to a collection Group papers in collections to compare them, chat with them and export them. Continue with Google Create a free account Log in

Export BibTeX · RIS (Zotero, Mendeley, EndNote) · Obsidian (Markdown) · Notion (Markdown)

Advanced tools Premium

For researchers who follow a field closely: citation alerts, journal-club slides, version comparison and Zotero export. Discover Premium

Zotero

Citation alerts Citation alerts guide

Who works on it? The people and institutions who publish on its topic

Weekly letter Presented in "Biology and medicine this week" of 9 November 2026. Biology and medicine this week: Inherited protection, bacterial clocks and a revised cattle family tree

Journal club Premium+ Slides to present it Propose for the journal club

Talk about it in public Premium+ Press kit: release, questions, hype check Press kit guide

Disclaimer: The AI-based summarization tool and virtual assistant provided on this website may not always provide accurate and complete summaries or responses. We encourage you to carefully review and evaluate the generated content to ensure its quality and relevance to your needs.

CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease

The essentials

Question

Method

Findings

Limitations

Why it matters

Read further

Definitions

Could Removing EBV-Infected B Cells Help Explain Lasting Remission?

What the Researchers Examined

A More Activated B-Cell Profile in Autoimmune Disease

Different Patterns After CAR T-Cell Therapy and Rituximab

What the Remission Results May Mean

Important Caveats

The Takeaway

Ask questions about this paper to our AI assistant

Tools for this paper

Advanced tools Premium

Papers around this one

Closest papers

Prior work it builds on

Go further

Cite this paper (BibTeX)